Efficacy and safety of novel oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolism
Abstract
The aim of this meta-analysis was to systematically evaluate the efficacy and safety of novel oral anticoagulants and vitamin K antagonists in the treatment of venous thromboembolism. A total of 6 studies met the inclusion criteria and a total of 19,350 patients with venous thromboembolism were included. Among them, rivaroxaban (3 RCTs, n=90/3,449/4,832); dabigatran (2 RCTs, n=200/2,539); edoxaban (1 RCT, n=8,240). The results of meta-analysis showed that the total bleeding rate after treatment with the vitamin K antagonist group was higher than with the new oral anticoagulant group (OR=0.82, 95% confidence interval 0.75-0.90, p<0.0001), and the difference was highly statistically significant. Overall, new oral anticoagulants are comparable to vitamin K antagonists, but new oral anticoagulants can reduce the occurrence of bleeding events and the safety was superior to vitamin K antagonists.
References
Angchaisuksiri P. Venous thromboembolism in Asia: An unrecognised and under-treated problem? Thromb Haemost. 2011; 106: 585-90.
Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363: 2499-510.
Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369: 1406-15.
Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366: 1287-97.
Castellucci LA, Cameron C, Le GG, Rodger MA, Coyle D, Wells PS, Clifford T, Gandara E, Wells G, Carrier M. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: A systematic review and meta-analysis. JAMA. 2014; 312: 1122.
Chao TF, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung FP, Chen TJ. Oral anticoagulation in very elderly patients with atrial fibrillation: A nationwide cohort study. Circulation 2018; 2018.
Conway SE, Hwang AY, Ponte CD, Gums JG. Laboratory and clinical monitoring of direct acting oral anticoagulants: What clinicians need to know. Pharmacother J Human Pharmacol Drug Therap. 2017; 37: 236-48.
Dentali F, Di MM, Gianni M, Ambrosino P, Squizzato A, Ageno W. Non-vitamin K oral anticoagulants in patients with pulmonary embolism: A systematic review and meta-analysis of the literature. Intern Emerg Med. 2015; 10: 507-14.
Didi S, Yuling Y, Dongdong Y. Dabigatran versos warfarin in the treatment of venous thromboembolism. Shock 2017; 45: 591-97.
Haaland GS, Falk RS, Straume O, Lorens JB. Association of warfarin use with lower overall cancer incidence among patients older than 50 years. JAMA Intern Med. 2017; 177: 1774-80.
Holbrook AM, Pereira JA, Labiris R, Mcdonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005; 165: 1095.
Imberti D, Becattini C, Bernardi E, Camporese G, Cuccia C, Dentali F, Paretti D. Multidisciplinary approach to the management of patients with pulmonary embolism and deep vein thrombosis: A consensus on diagnosis, traditional therapy and therapy with rivaroxaban. Intern Emerg Med. 2018: 2018.
Inohara T, Xian Y, Liang L, Matsouaka RA, Saver JL, Smith EE, Schwamm LH, Reeves MJ, Hernandez AF, Bhatt DL. Association of intracerebral hemorrhage among patients taking non-vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital mortality. JAMA. 2018; 319: 463-73.
Investigators EP, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Investigators PE. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, 2012.
Investigators TE. Oral rivaroxaban for symptomatic venous thromboembolism. New Engl J Med. 2010; 363: 2499-510.
Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149: 315-52.
Kyrle PA, Eichinger S. Clinical scores to predict recurrence risk of venous thromboembolism. Thromb Haemostasis. 2012; 107: 1061-64.
Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008; 451: 914-18.
Mazzolai L, Aboyans V, Ageno W, Agnelli G, Alatri A, Bauersachs R, Brekelmans MP, Büller HR, Elias A, Farge D. Diagnosis and management of acute deep vein thrombosis: A joint consensus document from the European society of cardiology working groups of aorta and peripheral circulation and pulmonary circulation and right ventricular function. Eur Heart J. 2017: 2017.
Mega JL, Simon T. Pharmacology of antithrombotic drugs: An assessment of oral antiplatelet and anticoagulant treatments. Lancet 2015; 386: 281-91.
Moreno AIF, DÃaz RMM, Navarro MJG. Anticoagulantes orales directos: Puesta al dÃa. Medicina ClÃnica. 2017.
Pan KL, Singer DE, Ovbiagele B, Wu YL, Ahmed MA, Lee M. Effects of non–vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: A systematic review and meta analysis. J Am Heart Assoc. 2017; 6: e005835.
Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361: 2342-52.
Sun MT, Wood MK, Chan W, Selva D, Sanders P, Casson RJ, Wong CX. Risk of intraocular bleeding with novel oral anticoagulants compared with warfarin: A systematic review and meta-analysis. JAMA Ophthalmol. 2017; 135: 864-70.
Vora P, Sorianogabarró M, Suzart K, Brobert GP. Limited evidence on persistence with anticoagulants, and its effect on the risk of recurrence of venous thromboembolism: A systematic review of observational studies. Patient Prefer Adherence. 2016; 10: 1657-65.
Wakakura S, Hara F, Fujino T, Hamai A, Ohara H, Kabuki T, Harada M, Ikeda T. Comparison of direct oral anticoagulants and warfarin in the treatment of deep venous thrombosis in the chronic phase. Int Heart J. 2018; 59: 126-35.
Ym H. Research on comparison of rivaroxaban and warfarin in treatment of venous thromboembolism. Shock 2017; 45: 591-97.
Apply citation style format of Bangladesh Journal of Pharmacology
Copyright (c) 2018 Haitang Xie, Maodi Xu, Qingquan Xue, Zhichen Pu, Zijing Wu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
